|Table of Contents|

Efficacy and safety of anlotinib in the treatment for advanced non-small cell lung cancer:A Meta-analysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 02
Page:
242-248
Research Field:
Publishing date:

Info

Title:
Efficacy and safety of anlotinib in the treatment for advanced non-small cell lung cancer:A Meta-analysis
Author(s):
JIANG Zhongxiu; CUI Guoyuan; ZHANG Xiaoye
The Fourth Oncology Department,Shengjing Hospital of China Medical University,Liaoning Shenyang 110020,China.
Keywords:
anlotinib; non-small cell lung cancer; effective rate; response rate; adverse reaction
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2021.02.013
Abstract:
Objective:To evaluate the efficacy and safety of anlotinib in the treatment for advanced non-small cell lung cancer by Meta-analysis.Methods:Studies were identified by searching Pubmed,EMbase,Cochrane Library,CNKI,Wanfang,VIP and CBM by January 2020.Clinical trials of anlotinib in the treatment for advanced non-small cell lung cancer were included.Choose studies according to the inclusion criteria and exclusion criteria,and evaluate quality retrieve data.Meta-analysis was performed for the results of studies by using RevMan 5.3 software.Results:4 studies were included.They were all high quality studies.The results showed:The effective rate［OR=2.03,95%CI(1.04,3.96),P=0.04］,the response rate［OR=7.56,95%CI(5.21,10.97),P＜0.000 01］,the progression-free survival［HR=0.26,95%CI(0.21,0.33),P＜0.000 01］ and the overall survival［HR=0.72,95%CI(0.58,0.89),P=0.002］ of anlotinib in the treatment for advanced non-small cell lung cancer were significantly superior to placebo.The incidence of hypertension,hand-foot syndrome,hypothyroidism,haemoptysis and diarrhea were higher in the anlotinib(P＜0.05).Conclusion:Anlotinib could improve the efficacy and prolong the survival time of advanced non-small cell lung cancer,and its safety could be in control.

References:

［1］ 韩宝惠,李凯,周彩存,等.晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2019版）［J］.中国肺癌杂志,2019,22(7):401-412. HAN BH,LI K,ZHOU CC,et al.Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2019 edition)［J］.Chin J Lung Cancer,2019,22(7):401-412.
［2］ 何婧怡,吴芳,胡春宏.第三代EGFR-TKIs治疗晚期非小细胞肺癌的耐药机制及应对策略研究进展［J］.肿瘤防治研究,2019,46(10):938-945. HE JY,WU F,HU CH.Research progress on resistance mechanisms and overcoming strategies to third generation EGFR-TKIs in advanced non-small cell lung cancer［J］.Cancer Res Prev Treat,2019,46(10):938-945.
［3］ 辛涛,金发光,刘伟,等.盐酸安罗替尼胶囊治疗晚期非小细胞肺癌的临床研究［J］.中华肺部疾病杂志(电子版）,2018,11(5):559-562. XIN T,JIN FG,LIU W,et al.Anlotinib hydrochloride capsules in the treatment of advanced non－small cell lung cancer patients:a clinical study［J］.Chin J Lung Dis(Electronic Edition),2018,11(5):559-562.
［4］ SHAO L,WANG WX,SONG ZB,et al.The effificacy and safety of anlotinib treatment for advanced lung cancer［J］.Onco Targets Ther,2019,12:6549-6554.
［5］ HAN BH,LI K,ZHAO YZ,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small cell lung cancer:a multicentre,randomised phase II trial (ALTER0302)［J］.Br J Cancer,2018,118(5):654-661.
［6］ 斯晓燕,王汉萍,张晓彤,等.安罗替尼治疗晚期非小细胞肺癌16例临床分析［J］.中华内科杂志,2018,57(11):830-834. SI XY,WANG HP,ZHANG XT,et al.Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer［J］.Chin J Intern Med,2018,57(11):830-834.
［7］ 杨莅,王启鸣.安罗替尼三线及三线后治疗非小细胞肺癌的疗效研究［D］.郑州：郑州大学,2018. YANG L,WANG QM.The efficacy of Anlotinib as a third or further line treatment in patients with advanced NSCLC［D］.Zhengzhou：Zhengzhou University,2018.
［8］ ZHOU M,CHEN XY,ZHANG H,et al.China National Medical Products administration approval summary:anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy［J］.Cancer Commun,2019,39:36.
［9］ 林建光,许天文,解方为,等.安罗替尼二线治疗38例铂类耐药晚期肺腺癌患者观察［J］.中国肿瘤临床,2019,46(19):999-1002. LIN JG,XU TW,XIE FW,et al.Efficacy of anlotinib as a second-line treatment in 38 patients with platinum-resistant advanced lung adenocarcinoma［J］.Chin J Clin Oncol,2019,46(19):999-1002.
［10］ 聂思茹,张晓晔.乳腺癌患者焦虑抑郁的研究进展［J］.现代肿瘤医学,2019,27(6):1080-1083. NIE SR,ZHANG XY.Research progress on anxiety and depression of breast cancer patients［J］.Modern Oncology,2019,27(6):1080-1083.
［11］ 王俊,冉凤鸣,金兵.安罗替尼治疗恶性肿瘤的临床研究进展［J］.中国肿瘤,2019,28(5):359-366. WANG J,RAN FM,JIN B.Progress on clinical research of Anlotinib in cancer treatment［J］.China Cancer,2019,28(5):359-366.
［12］ WANG LL,HE Z,YANG S,et al.The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC):a subgroup analysis of ALTER0303 trial［J］.Transl Lung Cancer Res,2019,8(5):575-583.
［13］ CHI Y,FANG Z,HONG X,et al.Safety and efficacy of anlotinib,a multikinase angiogenesis inhibitor,in patientswith refractory metastatic soft-tissue sarcoma［J］.Clin Cancer Res,2018,24(21):5233-5238.
［14］岳恺.安罗替尼胶囊联合顺铂治疗非小细胞肺癌恶性胸腔积液的价值研究［J］.中国合理用药探索,2018,15(11):84-93. YUE K.Study on the value of erlotinib capsules combined with cisplatin in the treatment of malignant pleural effusion in non-small cell lung cancer［J］.Chinese Journal of Rational Drug Use,2018,15(11):84-93.
［15］ LIN B,SONG X,YANG D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRβ and FGFR1［J］.Gene,2018,654:77-86.
［16］ RUAN X,SHI X,DONG Q,et al.Antitumor effects of anlotinib in thyroid cancer［J］.Endocr Relat Cancer,2019,26(1):153-164.
［17］ 罗详冲,刘晶晶,李高峰.安罗替尼治疗晚期恶性肿瘤的研究进展［J］.肿瘤,2019,39(12):1025-1030. LUO XC,LIU JJ,LI GF.Progress of anlotinib in treatment of advanced malignant tumors［J］.Tumor,2019,39(12):1025-1030.
［18］ HAN B,LI K,WANG Q,et al.Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer:the ALTER 0303 phase 3 randomized clinical trial［J］.JAMA Oncol,2018,4(11):1569-1575.
［19］ CHENG Y,WANG Q,LI K,et al.OA13.03 anlotinib as third-line or further-line treatment in relapsed SCLC:a multicentre,randomized,double-blind phase 2 trial［J］.J Thorac Oncol,2018,13(10):S351-S352.
［20］ 黄鲁众,张晓晔,刘艳,等.阿瑞匹坦联合5-HT3 受体拮抗剂和地塞米松预防化疗相关性恶心和呕吐的Meta分析［J］.现代肿瘤医学,2015,23(15):2198-2203. HUANG LZ,ZHANG XY,LIU Y,et al.Efficacy of aprepitant plus 5-HT3 receptor antagonist and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting:A Meta analysis［J］.Modern Oncology,2015,23(15):2198-2203.

Memo

Memo:
北京医卫健康公益基金会医学科学研究基金（编号:YWJKJJHKYJJ-F2214A）
Last Update: 1900-01-01